Latest Content

Krieger Scientific's Joseph Morwald on why well-positioned pharma companies treat the FDA as a partner, invest in unbiased third-party oversight, and continuously raise the bar on compliance rather than treating it as a fixed threshold to clear.

The AstraZeneca–BMS merger story explained: what was reported, what was denied, what regulators would scrutinize, and what it means for pharma.

In today's Pharmaceutical Executive Daily, Jazz Pharmaceuticals agrees to acquire Actio Biosciences, Novo Nordisk, Innate Pharma, and Innovent Biologics strike a trio of new partnerships, and a Veeva executive discusses how agentic AI is surfacing HCP insights that traditional field reporting has historically missed.

Such enterprises will be defined not only by breakthrough therapies but also by agile leadership, AI-enabled transformation and patient-centered operating models that accelerate innovation into real-world impact.

Jazz Pharmaceuticals agrees to acquire Actio Biosciences for $820 million upfront plus up to $500 million in milestones for ABS-1230.

Insights into the "differentiation paradox" from a study of 340 drug launches.

Novo Nordisk selects AWS as its preferred AI partner for drug discovery, Innate Pharma partners with Sobi, and Innovent Biologics secures exclusive commercialization rights for Vanflyta in China.

Veeva's president of commercial strategy discusses how agentic AI is surfacing the treatment barriers and HCP insights that traditional call reporting was never built to capture.

Krieger Scientific's Joseph Morwald on why unverified AI-generated documentation in pharma is a complex issue with potentially significant consequences.

Amazon Pharmacy is now delivering GLP-1 weight management medications to eligible Medicare patients.

Tarsus Pharmaceuticals has agreed to acquire Alkeus Pharmaceuticals for $450 million, centering the deal on gildeuretinol.

FDA has granted accelerated approval to Replimune's Tudriqev plus nivolumab for anti-PD-1-refractory unresectable advanced cutaneous melanoma.

Krieger Scientific's Joseph Morwald explains how siloed departments, disconnected systems, and a lack of cross-functional accountability are creating the structural compliance gaps that FDA warning letters keep exposing.